An empty syringe is shown on a table at Ronald Reagan UCLA Medical Center after a care worker received the COVID-19 vaccine on Dec. 16 in Westwood, California.

An empty syringe is shown on a table at Ronald Reagan UCLA Medical Center after a care worker received the COVID-19 vaccine on Dec. 16 in Westwood, California.

How Will People Actually Get COVID-19 Vaccines?

With COVID-19 vaccine distribution underway, how will people get them and what are the potential distribution pitfalls? An expert breaks down the logistics.

What are the logistical challenges of distributing different types of COVID-19 vaccines to millions of people, from urban centers to sparsely populated rural counties? Julie Swann has answers.

This article was originally published in Futurity. Edits have been made to this republication. It has been republished under the Attribution 4.0 International license.

Swann, a systems engineer with expertise in vaccine distribution whose work focuses on making health care and supply chains more efficient, effective, and equitable, is the department head and professor of the industrial and systems engineering department of at North Carolina State University.

Here, she digs into COVID-19 vaccine distribution and why it’s such a challenge:

Q: Will vaccines vary from state to state?

A: The Pfizer vaccine was approved recently in the US and has started to ship. It is expected that Moderna could receive approval soon with shipments shortly following. I expect both vaccines will go to all states. Once priority populations—such as hospital workers—have been vaccinated, and a larger number of doses becomes available, vaccines will also be sent to commercial pharmacies for distribution. Eventually we may have several more vaccines become available. Consumers may not even realize which they receive unless they have a specific medical condition that is relevant. That says, because these vaccines require two shots, delivered weeks apart, it is important for people to ensure that their second dose is the same type of vaccine as their first dose. This ensures they get the maximum potential immunity from the vaccine.

Q: How much time has to elapse between getting the shots? Why do the vaccines require multiple shots anyway?

A: For the Pfizer vaccine, one should have a second shot 21 days after the first. For the Moderna vaccine, the second dose comes 28 days later. This is not unusual, as there are several vaccines where multiple doses are recommended, including for Hepatitis A, Varicella (chicken pox), and others. We have never before had a vaccine for a coronavirus, so it is not surprising that it may take two doses to enable our systems to have full protection. Recently, the data showed that the first dose of Pfizer provided about 50% protection over the next few days, but that it provided 90+% after the second dose.

Q: What are the biggest logistical challenges to distributing the vaccine?

A: There are several! We talked about some of these challenges earlier this year.

Some people talk about the scale. For example, it will take approximately 500 million doses to vaccinate a significant portion of the US adult population, because most of the vaccines require two doses. As a comparison, this year we have a supply of 198 million doses of influenza vaccine, and the H1N1 pandemic response distributed more than 100 million doses in emergency settings. So the scale is impressive, but not insurmountable, especially given that the systems will build upon previously used practices.

One challenge is the cold chain that is required, especially for a vaccine like the one from Pfizer, which currently needs to be stored at -70 degrees Celsius (-94 degrees Fahrenheit). That is much colder than our freezer temperatures. Pfizer has developed a special thermal shipping box that can have dry ice added every five days for up to a total of 30 days. Once thawed it should be kept at 2-8 degrees C (refrigeration) for no more than five days. The shipping box contains about 1,000 to 5,000 doses, so it is likely to be more appropriate for cities, or locations that will host mass vaccination clinics.

The Moderna vaccine can be stored at -20 degrees C for months or at 2-8 degrees C for up to 30 days. Those shipments will contain a minimum of 100 doses each, so it may be appropriate for smaller locations, including rural ones. Fortunately, from the initial available data, those two vaccines have similar profiles in terms of safety and efficacy.

A third challenge is managing and using the information across the whole system. Our public health system is decentralized, with multiple entities making decisions. There are several information systems that have different functions and do not all talk to each other. On an everyday basis, the public health system does not need to have a robust information system tracking millions of products to their final destination for rapid response to changing supply and demand. There are also some new information systems being deployed; this could be helpful or it could add to the complexity.

Another challenge is people. Namely, how do we reach people, including in fair and equitable ways? How do we make sure that people have trustworthy information about safety and efficacy?

We are already seeing misinformation campaigns, and there are documented concerns around vaccine hesitancy. The people managing logistics systems should remember that human beings are the ultimate consumers. That means logistics should include humans in the loop in multiple ways to support equitable, just outcomes that take into account patient opinions.

Q: Why do some COVID-19 vaccines have to be kept ultra-cold?

A: These are the first mRNA vaccines authorized for widespread use! Scientists have been working for more than a decade to get to this point. Messenger RNA (mRNA) provides a set of instructions to your cells. To get into the cells, it is encased in a lipid fatty acid. The lipids need to be kept cold so they do not merge with each other, like M&M’s need a coating to not become a melted chocolate mess.

These vaccines do not include live virus, and they do not interact with a person’s DNA. The ingredients are known and have not generated concern.

There are also other vaccines being developed, with several types of technologies. The Johnson & Johnson vaccine is built on an adenovirus (like its recent Ebola vaccine), and the Novavax one on a protein (like its candidate flu vaccine, Nanoflu).

The temperature for a particular vaccine can be specific, based on its specific formulation and the testing that the company has done to show stability. The Ebola vaccine distributed in West Africa also needed to be kept very cold, which was done through a combination of freezers and a new type of thermos.

Q: What is being done, that we know of, to address all of these challenges?

A: We have known for months about the scale, and certainly everyone in the country has become aware that supply chain disruptions can have negative impacts. So people have been working on developing solutions. Pfizer and Moderna have been testing the vaccines to allow for relaxation of temperatures in ways that maintain the vaccine stability and potency. Massive educational campaigns have already begun to address vaccine hesitancy.

Also, the National Academies of Science, Engineering, and Medicine report on allocating vaccines, and recommendations from the CDC’s Advisory Committee on Immunization Practices recommendations, are important steps toward beginning to address issues around inequities and disparities in outcomes that have already been occurring. We have also seen a number of companies who are innovating to solve problems, including the development of mobile freezers, ultra-low cold devices, forecasting systems, and others.

Source: NC State

This article was originally published in Futurity. Edits have been made to this republication. It has been republished under the Attribution 4.0 International license.